Application No.

Docket No.

09/872,761

340078.401

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Paragraph beginning at page 11, line 17, has been amended as follows:

A 205 base pair segment of the lacI gene with the sequence (SEQ ID NO:1):

AATTCATAAA GGAGATATCA TATGAAACCG GTAACGTTAT ACGACGTCGC TGAATACGCC

61 GGCGTTTCTT ACCAGACCGT TTCTAGAGTG GTTAACCAGG CTTCACATGT TAGCGCTAAA

121 ACCCGGGAAA AAGTTGAAGC TGCCATGGCT GAGCTCAACT ACATCCCGAA CCGTGTTGCG

181 CAGCAGCTGG CTGGTAAACA AAGCT

is synthesized using a set of overlapping double-stranded oligonucleotides.

Paragraph beginning at page 14, line 12, has been amended as follows:

One common side reaction of oligonucleotide synthesis is the formation of diaminopurine from a dG residue in the DNA chain. Modified oligonucleotides containing 2,6-diaminopurine are obtained from Trilink Biotechnologies (San Diego, CA) and incorporated into the 205 bp lacI gene fragment. Four samples were prepared as described in Example 1, with one diaminopurine residue (labeled **D** below) substituted for a dG residue in each sample.

Oligonucleotide	Fragment Name	Base Replaced	SEQ ID NO:
5 ACCGTTTCTADAGTGGTTAACCAGG 3	D-T86	86	<u>2</u>
5 ACCGTTTCTAGADTGGTTAACCAGG 3	D-T88	88	<u>3</u>
5´ GGAAAAA D TTGAAGCTGCCATGGCT 3´	D-T133	133	<u>4</u>
5 TTDCGCAGCAGCTGGCTGGTAAACAA 3	D-T178	178	ς .

Paragraph beginning at page 15, line 3, has been amended as follows:

A second common side reaction of oligonucleotide synthesis is deamination of the N4-amine of deoxycytidine to form a uracil (dU) in the DNA chain. Modified oligonucleotides containing uracil (dU) are obtained from Midland Certified Reagent Company (Midland, TX) and incorporated into the 205 bp lacI gene fragment. Two samples were prepared as described in Example 1, with one uracil residue (labeled **dU** below) substituted for a dC residue in each sample.

Oligonucleotide	Fragment Name	Base Replaced	SEQ ID NO:
5 TGAAGCCTGGTTAACCACT dU TAGAA 3	U-B86	86	<u>6</u>
5 AGCTCAGCCATGGCAGCTTCAA du TT 3	U-B133	133	7

Paragraph beginning at page 15, line 13, has been amended as follows:

A third common side reaction of oligonucleotide synthesis is the formation of abasic sites by depurination of protected adenosine residues during chain elongation. Modified oligonucleotides containing uracil are obtained from Midland Certified Reagent Company (Midland, TX) and incorporated into the 205 bp lacI gene fragment. Two samples were prepared as described in Example 1, with one uracil residue (labeled **dU** below) substituted for a dA residue in each sample.

Oligonucleotide	Fragment Name	Base Replaced	SEQ ID NO:
5' AGCTCAGCCATGGCAGCTTCA du CTT 3'	A-B134	134	<u>8</u>
5' TTGCGC dU GCAGCTGGCTGGTAAACAA 3'	A-T182	182	<u>9</u>

Paragraph beginning at page 16, line 7, has been amended as follows:

The thermal and gradient conditions for isolating chemically-pure enriched sequence are calculated using the DHPLC Melt Program (http://insertion.stanford.edu/melt.html) available from Stanford University (Palo Alto, CA) and available for license from the Stanford University Office of Technology Licensing referring to the docket number S95-024. The 4 base single-

stranded region on either end of the 205 base pair fragment is removed to give the following 197 base pair sequence (SEQ ID NO: 10).

lac I Region

Paragraph beginning at page 20, line 14, has been amended as follows:

The control and the four sequences containing the synthesis byproducts are listed below:

- 5'- ATTCGCCCTTTGCCACTAAGCACCAGCGAAACGGTACTTACCGACACG-3' Control (SEQ ID NO:11)
- 5'-ATTCGCCCTTTGCCACTAAGCACCAGCGAAACGGTACT_ACCGACACG-3' n-1 (SEQ ID NO:12)
- 5'-ATTCGCCCTTTGCCACTAAGCACCAGCGAAACGGTACTT<u>T</u>ACCGACACG-3' n+ (SEQ ID NO:13)
- 5'-ATTCGCCCTTTGCCACTAAGCACCAGCGAAACGGTACTT<u>G</u>CCGACACG-3' T/G Mismatch (SEQ ID NO:14)
- 5'-ATTCGCCCTTTGCCACTAAGCACCAGCGAAACGGTACTTA<u>G</u>CGACACG-3' G/G Mismatch (SEQ ID NO:15)